

AbbVie A/S

Emdrupvej 28C, 2100 København Ø

CVR no. 34 46 28 28

Annual report 2017

Approved at the Company's annual general meeting on 28 May 2018

Chairman:



Ulrik Bangsbo Hansen

Contents

Statement by the Supervisory and Executive Board	2
Independent auditors' report	3
Management's review	5
Company details	5
Financial highlights	6
Financial statements for the period 1 January – 31 December	8
Income statement	8
Balance sheet	9
Statement of changes in equity	11
Notes to the financial statements	12

Statement by the Supervisory and Executive Boards

The Supervisory and Executive Boards have today discussed and approved the annual report of AbbVie A/S for the financial year 1 January – 31 December 2017.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

It is our opinion that the financial statements give a true and fair view of the Company's financial position at 31 December 2017 and of the results of the Company's operations and cash flows for the financial year 1 January – 31 December 2017.

Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.

We recommend that the annual report be approved at the annual general meeting.

Copenhagen, 28 May 2018

Executive Board:



Christina Dyreborg Jeppesen

CEO



Supervisory Board:

William Joseph Chase

Chairman


Christina Dyreborg Jeppesen
Tom Jensen Schjødt

Independent auditors' report

To the shareholders of AbbVie A/S

Opinion

We have audited the financial statements of AbbVie A/S for the financial year 1 January – 31 December 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2017 and of the results of the Company's operations for the financial year 1 January – 31 December 2017 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit conducted in accordance with ISAs and additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.

Independent auditors' report

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.

Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 28 May 2018
Ernst & Young
Godkendt Revisionspartnerselskab
CVR no. 30 70 02 28



Christian Schwenn Johansen
State Authorised Public Accountant
MNE no.: mne33234

Management's review

Company details

Name	AbbVie A/S
Address, zip code, city	Emdrupvej 28C, 2100 Copenhagen Ø
CVR no.	34 46 28 28
Financial year	1 January - 31 December
Established	14 March 2012
E-mail	finance.dk@abbvie.com
Telephone	+45 72 30 20 28
Supervisory Board	William Joseph Chase, Chairman Christina Dyreborg Jeppesen Tom Jensen Schjødt
Executive Board	Christina Dyreborg Jeppesen, CEO
Auditors	Ernst & Young Godkendt Revisionspartnerselskab Osvald Helmuths Vej 4, 2000 Frederiksberg
Bankers	Handelsbanken

Management's review

Financial highlights

DKK	2017	2016	2015	2014	2013
-----	------	------	------	------	------

Key figures

Revenue	653 888 872	641 398 058	568 234 723	535 802 107	525 506 337
Operating profit	28 136 052	35 391 474	30 148 618	19 623 987	15 502 389
Net financials	18 034	-93 233	-162 511	-279 385	-172 159
Profit for the year	20 902 364	26 255 288	21 523 179	13 119 760	10 590 713

Balance sheet total	210 474 773	211 017 684	171 116 342	210 544 683	226 027 613
Investments in property, plant and equipment	763 474	880 041	2 139 078	1 652 166	912 156
Equity	119 790 837	118 888 473	92 633 185	71 110 007	57 990 247

Financial ratios in %

Return on assets	13,4	16,7	17,5	9,2	6,8
Equity ratio	56,9	56,3	54,1	33,8	25,7
Return on equity	17,4	22,1	23,2	16,4	16,3

Average number of full-time employees	78	84	96	94	83
---------------------------------------	----	----	----	----	----

Management's review

The company's business review

The company's activities consist of marketing, sale and distribution of pharmaceutical products to the health sector in Denmark, the Faroe Islands and Iceland.

Recognition and measurement uncertainties

Management evaluates that no certain risks are related to recognition and measurement in connection with the presentation of the annual report.

Financial review

In 2017, the company's revenue came in at DKK 553,888,872 against DKK 541,398,058 last year. The income statement for 2017 shows a profit of DKK 20,902,364 against DKK 26,255,288 last year, and the balance sheet at 31 December 2017 shows equity of DKK 119,790,837.

The management considers the company's financial performance in the year satisfactory.

Non-financial matters

No other non-financial matters have been identified.

Knowledge resources

The company's future economic viability is dependent on the research and development work undertaken by the group, which is described further below. As the company's activities consist of marketing, sale and distribution, knowledge resources in these areas are of significant importance to the future success of the business.

Special risks

Parallel imports and changes in the European reference prices have an impact on the performance of the company.

Impact on the external environment

Management does not consider the company's impact on the external environment significant.

Research and development activities

Future income from products is dependent on the success of research and development activities within the group.

Statutory CSR report

The company does not have any separate policies for CSR in general, including human rights, environment and the company's climate impact. For further information on the groups policies, see here:
<http://www.abbvie.com/responsibility/home.html>

Account of the gender composition of management

AbbVie A/S has an equal distribution of men and women both on the board of directors and in the other management.

Supervisory board comprises of one woman and two men (33.33%/66.67%).

Other management consists of three men and six women (33.33%/66.67%).

According to The Danish Business Authority this percentage is considered an equal gender balance. The company does not have a policy for the gender composition of management.

Post balance sheet events

No significant events have occurred subsequent to the financial year.

Outlook

The company expects that the revenue will be in the range DKK 460-470MM and profit before tax around DKK 20MM for 2018. During the second half of 2018, competition from new products and the impact of biosimilar products may impact future growth.

Financial statements for the period 1 January – 31 December

Income statement

Note	DKK	<u>2017</u>	<u>2016</u>
2	Revenue	553 888 872	541 398 058
	Cost of sales	391 615 130	368 895 433
	Other external expenses	38 591 053	49 298 209
	Gross margin	<u>123 682 689</u>	<u>123 204 416</u>
3	Staff costs	93 477 887	85 732 993
4	Amortization/depreciation of intangible assets and property, plant and equipment	2 068 750	2 079 950
	Operating profit	<u>28 136 052</u>	<u>35 391 474</u>
5	Financial income	40 174	3 085
6	Financial expenses	22 140	96 318
	Pre-tax profit	<u>28 154 086</u>	<u>35 298 241</u>
7	Tax for the year	7 251 722	9 042 953
	Profit for the year	<u><u>20 902 364</u></u>	<u><u>26 255 288</u></u>
	Recommended appropriation of the profit for the year		
	Dividend proposed for the year	0	20 000 000
	Retained earnings	<u>20 902 364</u>	<u>6 255 288</u>
		<u><u>20 902 364</u></u>	<u><u>26 255 288</u></u>

Financial statements for the period 1 January – 31 December

Balance sheet

Note	DKK	<u>2017</u>	<u>2016</u>
	ASSETS		
	Non-current assets		
8	Intangible assets		
	Goodwill	<u>0</u>	<u>419 736</u>
		<u>0</u>	<u>419 736</u>
9	Property, plant and equipment		
	Plant and machinery	1 097 799	1 029 709
	Fixtures and fittings, plant and equipment	<u>1 759 135</u>	<u>2 715 853</u>
		<u>2 856 934</u>	<u>3 745 563</u>
10	Financial assets		
	Other receivables	<u>2 256 823</u>	<u>2 256 823</u>
		<u>2 256 823</u>	<u>2 256 823</u>
	Total non-current assets	<u>5 113 757</u>	<u>6 422 122</u>
	Current assets		
	Inventories		
	Finished goods and goods for resale	<u>1 102 174</u>	<u>1 155 159</u>
		<u>1 102 174</u>	<u>1 155 159</u>
11	Receivables		
	Trade receivables	125 858 352	128 080 946
	Receivables from group entities	72 897 098	69 706 354
12	Deferred tax	227 804	158 026
	Other receivables	1 513	18 000
13	Prepayments	<u>2 295 962</u>	<u>2 476 452</u>
		<u>201 280 529</u>	<u>200 439 778</u>
	Cash	<u>2 978 314</u>	<u>3 000 626</u>
	Total current assets	<u>205 361 016</u>	<u>204 595 563</u>
	TOTAL ASSETS	<u>210 474 773</u>	<u>211 017 684</u>

Financial statements for the period 1 January – 31 December

Balance sheet

Note	DKK	2017	2016
	EQUITY AND LIABILITIES		
	Equity		
14	Share capital	501 000	501 000
	Retained earnings	119 289 837	98 387 473
	Dividend proposed for the year	0	20 000 000
	Total equity	119 790 837	118 888 473
15	Liabilities		
	Current liabilities		
	Trade payables	8 205 093	7 486 556
	Payables to group entities	44 768 330	46 280 944
	Income taxes payable	140 828	650 746
	Other payables	37 569 585	37 710 864
		90 683 936	92 129 211
	Total current liabilities	90 683 936	92 129 211
	TOTAL EQUITY AND LIABILITIES	210 474 773	211 017 684

Financial statements for the period 1 January – 31 December
Statement of changes in equity

Note	DKK	<u>Share capital</u>	<u>Retained earnings</u>	<u>Dividend proposed for the year</u>	<u>Total</u>
	Equity at 1 January 2017	501 000	98 387 473	20 000 000	118 888 473
	Dividend distribution	0	0	-20 000 000	-20 000 000
20	Profit for the year, cf. appropriation of profit	<u>0</u>	<u>20 902 364</u>	<u>0</u>	<u>20 902 364</u>
	Equity at 31 December 2017	<u>501 000</u>	<u>119 289 837</u>	<u>0</u>	<u>119 790 837</u>

Financial statements for the period 1 January – 31 December

Notes to the financial statements

1 Accounting policies

The annual report of AbbVie A/S for 2017 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to large reporting class C entities.

Effective 1 January 2016, the Company has adopted act no. 738 of 1 July 2015.

Omission to present a cash flow statement

The cash flow statement has not been presented, cf. ARL (Danish Financial Statements Act) section 86(4). The cash flow statement is included in the consolidated accounts for AbbVie Inc., which can be obtained from the following website: <http://investors.abbvie.com/phoenix.zhtml?c=251551&p=irol-reportsannual>

Reporting currency

Currency translation

Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.

Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.

Income statement

Revenue

Income from the sale of goods and finished goods is recognised in revenue at the time of delivery and when the risk passes to the buyer, provided that the income can be made up reliably and is expected to be received.

Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.

Cost of sales

Cost of sales includes the cost of goods used in generating the year's revenue.

Other external expenses

Other external expenses include the year's expenses relating to the entity's core activities, including expenses relating to distribution, sale, advertising, administration, premises, bad debts, payments under operating leases, etc.

Staff costs

Staff costs include wages and salaries, including compensated absence and pensions, as well as other social security contributions, etc. made to the entity's employees. The item is net of refunds made by public authorities.

Financial statements for the period 1 January – 31 December

Notes to the financial statements

1 Accounting policies (continued)

Amortisation/depreciation of intangible assets and property, plant and equipment

The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.

Goodwill is amortised over the expected economic life, measured by reference to an assessment of, among other factors, the nature, earnings and market position of the acquired entity as well as the stability of the industry and the dependence on key staff.

The estimated useful lives and the residual value for intangible assets are as follows:

Goodwill	7 years
----------	---------

The amortisation period for goodwill exceeds 5 years, as the main product in the invested company is still patent protected.

Property, plant and equipment are depreciated on a straight-line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations and less expected residual value.

The expected useful lives and the residual value of the assets are as follows:

Plant and machinery	3-10 years
Fixtures and fittings, tools and equipment	3-10 years

The residual value is determined at the time of acquisition and are reassessed every year. Where the residual value exceeds the carrying amount of the asset, no further depreciation charges are recognised. In case of changes in the residual value, the effect on the depreciation charges is recognised prospectively as a change in accounting estimates.

Tax

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

Balance sheet

Intangible assets

Goodwill is measured at cost less accumulated amortisation and impairment losses.

Property, plant and equipment

Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.

Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.

Investments

Other investments comprise from other receivables, which covers rental deposits. Deposits are measured at nominal value.

Inventories

Inventories are measured at the lower of cost or market using weighted average cost method. Cost of goods for resale consists of purchase price plus delivery costs. The net realizable value of inventories is calculated as the estimated selling price less completion costs and costs incurred to execute sale.

Financial statements for the period 1 January – 31 December

Notes to the financial statements

1 Accounting policies (continued)

Impairment of fixed assets

Every year, intangible assets and property, plant and equipment are reviewed for impairment. Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount. Where an impairment loss is recognised on a group of assets, a loss must first be allocated to goodwill and then to the other assets on a pro rata basis.

Receivables

Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.

Prepayments

Prepayments recognised under 'Assets' comprise prepaid expenses regarding subsequent financial reporting years.

Cash and cash equivalents

Cash comprises cash balances and bank balances.

Proposed dividend

Dividends proposed for the financial year are presented as a separate item under 'Equity'.

Income tax

Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.

Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non-amortisable goodwill.

Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set-off against deferred tax liabilities within the same jurisdiction.

Other payables

Other payables are measured at net realisable value.

Segment information

Segment information is given for revenue broken down by business segment and geographical segment. The segmentation is in accordance with the entity's internal financial management.

Financial statements for the period 1 January – 31 December

Notes to the financial statements

1 Accounting policies (continued)

Financial ratios

Financial ratios are calculated in accordance with the Danish Finance Society's guidelines on the calculation of financial ratios.

Definition of financial ratios:

Return on assets:

Profit/loss from ordinary operating activities / Average assets * 100

Equity ratio:

Closing equity / Equity & liabilities at year-end * 100

Return on equity:

Profit/loss for the year / Average equity * 100

2 Segment information

Activities – primary segment

Abbvie has sales in various products and therapy areas, and several of these constitute significant segments. Therapy areas often only contain 1 product and therefore segmental disclosures split by therapy will show the net sales per product. The unit sales per product are published by IMS / DLI and thus such therapy segmentation will mean that the net price per unit can be determined by the public (as well as competitors). For competitive reasons, no therapy segment information has been disclosed.

Geographical – secondary segment

As the company's markets do not deviate significantly from one another, no geographical segment information has been disclosed.

DKK	<u>2017</u>	<u>2016</u>
3 Staff costs		
Wages and salaries	86 704 035	78 470 515
Pensions	6 392 204	6 608 603
Other social security costs	<u>381 648</u>	<u>653 875</u>
	<u>93 477 887</u>	<u>85 732 993</u>
Average number of full-time employees	<u>78</u>	<u>84</u>

By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.

4 Amortisation/depreciation of intangible assets and property, plant and equipment

Amortisation of intangible assets	419 736	419 850
Depreciation of property, plant and equipment	<u>1 649 014</u>	<u>1 660 100</u>
	<u>2 068 750</u>	<u>2 079 950</u>

Financial statements for the period 1 January – 31 December

Notes to the financial statements

DKK	<u>2017</u>	<u>2016</u>
5 Financial income		
Interest receivable, group entities	4 911	3 085
Exchange gain	<u>35 263</u>	<u>0</u>
	<u>40 174</u>	<u>3 085</u>
6 Financial expenses		
Interest expense, group entities	9	1 491
Exchange losses	0	22 803
Interest surcharge, income taxes	<u>22 131</u>	<u>72 024</u>
	<u>22 140</u>	<u>96 318</u>
7 Tax for the year		
Estimated tax charge for the year	7 159 308	8 896 592
Deferred tax adjustments in the year	-69 578	-7 927
Tax adjustments, prior years	161 992	154 288
Effect of change in tax year	<u>0</u>	<u>0</u>
	<u>7 251 722</u>	<u>9 042 953</u>
8 Intangible assets		
DKK		<u>Goodwill</u>
Cost at 1 January 2017		2 938 951
Cost at 31 December 2017		<u>2 938 951</u>
Amortisation at 1 January 2017		2 519 215
Amortisation in the year		<u>419 736</u>
Amortisation at 31 December 2017		<u>2 938 951</u>
Carrying amount at 31 December 2017		<u><u>0</u></u>

Financial statements for the period 1 January – 31 December

Notes to the financial statements

9 Property, plant and equipment

DKK	Plant and machinery	Fixtures and fittings, tools and equipment	Total
Cost at 1 January 2017	13 443 969	8 458 829	21 902 798
Additions	547 735	215 739	763 474
Disposals	-1 774 236	-485 142	-2 259 378
Cost at 31 December 2017	12 217 468	8 189 426	20 406 894
Impairment losses and depreciation at 1 January 2017	12 414 260	5 742 976	18 157 236
Depreciation	478 540	1 170 474	1 649 014
Reversal of depreciation and impairment losses, disposals	-1 773 131	-483 159	-2 256 289
Impairment losses and depreciation at 31 December 2017	11 119 669	6 430 291	17 549 960
Carrying amount at 31 December 2017	1 097 799	1 759 135	2 856 934

10 Financial assets

DKK	Other receivables and deposits
Cost at 1 January 2017	2 256 823
Additions	0
Disposals	0
Cost at 31 December 2017	2 256 823
Value adjustments at 1 January 2017	0
Value adjustments in the year	0
Value adjustments at 31 December 2017	0
Carrying amount at 31 December 2017	2 256 823

11 Receivables

Of the company's trade receivables DKK 0 falls due for payment after more than one year after the balance sheet date.

DKK	2017	2016
-----	------	------

12 Deferred tax

Deferred tax asset at 1 January	158 026	150 099
Adjustment of the deferred tax charge for the year	69 578	7 927
Deferred tax asset at 31 December	227 604	158 026

13 Prepayments

Prepayments include accrual of expenses relating to subsequent financial years, and mainly relate to congress, insurance policies and memberships.

Financial statements for the period 1 January – 31 December

Notes to the financial statements

DKK	<u>2017</u>	<u>2016</u>
14 Share capital		
Analysis of the company's share capital, DKK 501,000: 501 shares of DKK 1,000 each	<u>501 000</u>	<u>501 000</u>
	<u>501 000</u>	<u>501 000</u>

The company's share capital has remained DKK 501,000 in the past 5 years.

15 Liabilities

Of the company's liabilities DKK 0 falls due for payment after more than one year after the balance sheet date.

16 Security for loans

The company has not placed any assets or other as security for loans at 31 December 2017.

17 Contingent liabilities and other financial obligations

Other financial obligations

DKK	<u>2017</u>	<u>2016</u>
Rent and lease liabilities	15 333 224	9 604 055

Rent and lease liabilities include a rent obligation totalling DKK 9,607,484 in interminable rent agreements with remaining contract terms of 1-2 years. Furthermore, the company has liabilities under operating leases for cars totalling DKK 6,725,740 with remaining contract terms of 1-5 years.

Analysis of liabilities:

0-1 year	7 206 070	5 591 716
1-5 years	<u>8 127 154</u>	<u>4 012 339</u>
	<u>15 333 224</u>	<u>9 604 055</u>

Financial statements for the period 1 January – 31 December

Notes to the financial statements

18 Related parties

Parties exercising control

<u>Related party</u>	<u>Domicile</u>	<u>Basis for control</u>
AbbVie Inc.	North Chicago, Illinois, U.S.A.	Ultimate parent company

Information about shareholders holding 5% or more of the share capital or the voting rights

<u>Name</u>	<u>Domicile</u>
AbbVie Investments S.à.r.l. (reg. no. B166925)	16 Boulevard Royal, L-2449 Luxembourg

Receivables at 31 December

DKK	2017	2016
AbbVie Finance B.V.	65 730 875	64 494 660
AbbVie Inc.	7 166 223	4 649 869
AbbVie Limited	0	551 025
Other related parties	0	10 800
	<u>72 897 098</u>	<u>69 706 354</u>

Liabilities at 31 December

AbbVie Logistics B.V.	44 202 579	45 474 309
AbbVie Inc.	334 489	709 420
Other related parties	231 263	97 215
	<u>44 768 330</u>	<u>46 280 944</u>

Financial statements for the period 1 January – 31 December

Notes to the financial statements

18 Related parties (continued)

Profit and loss transactions

Cross reimbursement

DKK	2017	2016
AbbVie Inc.	22 500 140	20 547 933
AbbVie Limited	0	551 025
AbbVie Biopharmaceuticals GmbH	198 703	314 228
AbbVie Biotechnology Ltd.	0	217 676
Other related parties	139 448	144 189
	<u>22 838 291</u>	<u>21 775 052</u>

Expenses arising from related party transactions for the year

Purchase of goods

AbbVie Logistics B.V.	391 098 448	370 118 357
Other	134 357	59 952
	<u>391 232 805</u>	<u>370 178 309</u>

Purchase of services

AbbVie Inc.	10 079 547	12 592 258
AbbVie Logistics B.V.	2 589 275	2 388 727
AbbVie, L.da	93 298	259 841
AbbVie Biopharmaceutical SARL	740 027	245 398
AbbVie AS	225 407	218 764
AbbVie Corporation	236 589	122 638
AbbVie Biopharmaceuticals GmbH	1 023 959	52 853
Other related parties	110 572	174 185
	<u>15 098 675</u>	<u>16 054 664</u>

19 Fee for the auditors appointed by the company in general meeting

Fee for the statutory audit of the financial statements	312 426	310 000
Fee for tax consultancy	37 000	37 000
	<u>349 426</u>	<u>347 000</u>

20 Appropriation of profit

Recommended appropriation of profit

Dividend proposed for the year	0	20 000 000
Retained earnings	20 902 364	6 255 288
	<u>20 902 364</u>	<u>26 255 288</u>

21 Subsequent events

There are no significant changes planned in the company's operation in the foreseeable future.